Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | AHR | P35869 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CD38 | P28907 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134797 | 0.82 | CDK2 (0.57) | BRAFKDM4ENPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10134867 | 0.79 | RAB9A (0.58) | KMT2AAHRMEN1BRAFMAPT | |
| SCHEMBL560178 | 0.78 | ATR (0.63) | KMT2AAHRMEN1MAPTP4HTM | |
| SCHEMBL10134816 | 0.77 | JAK2 (0.53) | KMT2ABRAFSTAT3KDM4ENPC1 | |
| SCHEMBL10134810 | 0.74 | RAB9A (0.56) | KMT2AMEN1IRAK4KDM4ENPC1 | |
| SCHEMBL23413101 | 0.73 | MEN1 (0.54) | KMT2AMEN1BRAFMAPTSTAT3 | |
| SCHEMBL29887175 | 0.73 | MEN1 (0.54) | KMT2AMEN1BRAFMAPTSTAT3 | |
| SCHEMBL23413488 | 0.72 | MAPT (0.55) | KMT2AMEN1BRAFMAPTSTAT3 | |
| SCHEMBL23413150 | 0.72 | MAPT (0.53) | KMT2AMEN1BRAFMAPTSTAT3 | |
| SCHEMBL23413089 | 0.72 | MEN1 (0.55) | KMT2AAHRMEN1BRAFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962631-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120035407-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035407-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | KMT2A 1532/4885AHR 2654/4885MEN1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.